
NYSEHealthcareMedical - Devices
أحدث البيانات المتاحة
42.73 US$
+0.69 US$ · +1.64%
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
الإغلاق السابق
42.73 US$
+0.69 US$ · +1.64%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
نطاق اليوم
السعر الحالي 42.73 US$
نطاق 52 أسبوعًا
السعر الحالي 42.73 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
شراء
تقييم
95
قيمة جذابة جدًا
المشاعر
77
صعودي
المخاطر
50
مخاطر أعلى من المعتاد
الزخم
24
زخم متراجع
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
نطاق اليوم
السعر الحالي 42.73 US$
نطاق 52 أسبوعًا
السعر الحالي 42.73 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 20.07 مليار USD | 16.75 مليار USD | 14.24 مليار USD | 12.68 مليار USD | 11.89 مليار USD |
| تكلفة البضاعة المباعة | 6.22 مليار USD | 6.48 مليار USD | 5.41 مليار USD | 4.97 مليار USD | 4.43 مليار USD |
| الربح الإجمالي | 13.85 مليار USD | 10.27 مليار USD | 8.83 مليار USD | 7.71 مليار USD | 7.46 مليار USD |
| البحث والتطوير | 2.05 مليار USD | 1.62 مليار USD | 1.41 مليار USD | 1.32 مليار USD | 1.2 مليار USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 6.89 مليار USD | 5.98 مليار USD | 5.19 مليار USD | 4.52 مليار USD | 4.29 مليار USD |
| نفقات التشغيل | 9.88 مليار USD | 7.63 مليار USD | 6.65 مليار USD | 5.89 مليار USD | 5.54 مليار USD |
| دخل الفوائد | — | 107 مليون USD | 22 مليون USD | 10 مليون USD | 4 مليون USD |
| مصاريف الفوائد | 349 مليون USD | 387 مليون USD | 272 مليون USD | 464 مليون USD | 349 مليون USD |
| الاستهلاك والإطفاء | 1.37 مليار USD | 1.27 مليار USD | 1.2 مليار USD | 1.14 مليار USD | 1.09 مليار USD |
| الدخل التشغيلي | 3.97 مليار USD | 2.64 مليار USD | 2.18 مليار USD | 1.82 مليار USD | 1.92 مليار USD |
| صافي الدخل | 2.89 مليار USD | 1.85 مليار USD | 1.59 مليار USD | 698 مليون USD | 1.04 مليار USD |
تم تحديث حقائق الشركة 12 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
| الإجراء | تاريخ النفاذ | تفاصيل | تاريخ التسجيل | تاريخ الدفع |
|---|---|---|---|---|
تقسيم الأسهم | 6 نوفمبر 2003 | 2:1 | — | — |
تقسيم الأسهم | 1 ديسمبر 1998 | 2:1 | — | — |
ساري 6 نوفمبر 2003
2:1
ساري 1 ديسمبر 1998
2:1
صناديق متداولة تفصح عن تعرضها لهذا السهم.
State Street SPDR S&P 500 ETF1557.T117.51 مليار0.09%129.43 ترليون JPY0.09%122,850 JP¥+0.12%
Vanguard Morningstar Total Stock Market ETFVTI2.28 مليار0.10%2.3 ترليون USD0.03%381.94 US$+0.63%
Vanguard S&P 500 ETFVOO1.91 مليار0.11%1.8 ترليون USD0.03%715.59 US$+0.61%
iShares Core S&P 500 ETFIVV809.91 مليون0.09%896.44 مليار USD0.03%781.97 US$+0.60%
State Street SPDR S&P 500 ETFSPY742.23 مليون0.09%817.2 مليار USD0.09%778.57 US$+0.60%
Vanguard Morningstar Growth ETFVUG440.93 مليون0.11%384.6 مليار USD0.03%91.97 US$+0.72%
State Street Health Care Select Sector SPDR ETFXLV433.89 مليون1.00%43.54 مليار USD0.08%170.81 US$+1.58%
Vanguard Morningstar Value ETFVTV342.99 مليون0.13%262.4 مليار USD0.03%220.59 US$+0.44%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Growth ETFVUG
State Street Health Care Select Sector SPDR ETFXLV
Vanguard Morningstar Value ETFVTVالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.